Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study

Phase III trials have demonstrated the efficacy of risankizumab in moderate‐to‐severe Crohn's disease (CD), but no real‐world data are currently available. We aimed to assess the short‐term effectiveness and safety of risankizumab in patients with CD.

[1]  D. Rubin,et al.  S715 Clinical and Endoscopic Improvements With Risankizumab Induction and Maintenance Dosing versus Placebo Are Observed Irrespective of Number of Prior Failed Biologics , 2022, American Journal of Gastroenterology.

[2]  M. Dubinsky,et al.  Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials , 2022, The Lancet.

[3]  M. Dubinsky,et al.  Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial , 2022, The Lancet.

[4]  S. Ray,et al.  P340 Risankizumab in Inflammatory Bowel Disease: Real World Experience from a Pre-Approval Access Program , 2022, Journal of Crohn's and Colitis.

[5]  D. Franchimont,et al.  P576 Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort study , 2022, Journal of Crohn's and Colitis.

[6]  M. Lebwohl,et al.  Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up , 2021, The British journal of dermatology.

[7]  Siddharth Singh,et al.  AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. , 2021, Gastroenterology.

[8]  A. Griffiths,et al.  STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. , 2020, Gastroenterology.

[9]  Marien González-Lorenzo,et al.  Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta‐analysis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  M. Song,et al.  Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial , 2018, The British journal of dermatology.

[11]  A. Kaser,et al.  Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study , 2017, The Lancet.

[12]  J. Salleron,et al.  Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge. , 2016, Journal of Crohn's & colitis.

[13]  I. Leodolter.  [Crohn's disease]. , 1967, Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete.